期刊文献+

四种多肽负载的自体树突状细胞治疗恶性黑色素瘤近期疗效观察

Evaluation of the Curative Effect in the Near Future of the Dendritic Cells Pulsed with Four Polypeptide in the Treatment of Malignant Melanoma
原文传递
导出
摘要 目的探讨MAGE-3、Tyrosinase、MART-1、Gp-100等4种多肽负载的自体树突状细胞(DCs)治疗恶性黑素素瘤的安全性和近期疗效。方法分离患者外周血单核细胞,用重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)和白细胞介素-4(rhIL-4)体外诱导DCs,MAGE-3、tyrosinase、MART-1、Gp-100等4种多肽负载自体DCs,对10例HLA-A2阳性的恶性黑色素瘤患者进行4次DCs免疫治疗,观察其安全性、免疫功能和临床疗效。结果治疗中未出现明显不良反应,治疗后血清中IL-2、IL-12和IFN-γ水平呈明显上升趋势(P<0.05),6例患者的DTH检测阳性;7例有淋巴结转移的患者中,2例淋巴结转移消失,2例淋巴结肿大减小,3例淋巴结肿大稳定。结论多肽负载的自体DCs治疗恶性黑色素瘤可改善患者的免疫功能,激发特异性免疫反应,缓解病情,且不良反应少,为恶性黑色素瘤的免疫治疗提供了一条新途径。 Objective To evaluate the safety and curative effect in the near future of the dendritic cells(DCs) pulsed with four polypeptide (MAGE-3, Tyrosinase, MART-1 and Gp-100) in the treatment of malignant melanoma. Methods Mononuelear cells were isolated from the peripheral blood of 10 malig- nant melanoma patients. The DCs pulsed with four nona peptide( MAGE-3, tyrosinase, MART-1 and Gp- 100) were induced in vitro with rhGM-CSF and rhIL-4. The 10 HLA-A2-positive patients were treated with DCs for four times, and the safety, immunological function and clinical effect were observed. Results No severe adverse reaction was observed. The levels of IL-2, IL-12 and IFN-γ in the serum of patients rised significantly after the treatment. DTH test was positive in 6 patents. Of the 7 patients with lymph nodes metastasis, complete remission of the lymph nodes was observed in 2 patients, shrinkage in 2 patients and stabilization in 3 patients. Conclusion Treatment of malignant melanoma with DCs pulsed with polypeptide could improve the immunological function of the patients, stimulate specific immune response and modify symptoms with rare adverse reactions, and provide a new immunotherapy approach for treatment of malignant melanoma.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2009年第6期1126-1129,共4页 Suzhou University Journal of Medical Science
关键词 恶性黑色素瘤 树突状细胞 免疫治疗 malignant melanoma DCs immunotherapy
  • 相关文献

参考文献10

  • 1Redman BG, Chang AE, Whitfield J, et al. Phase I b trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma [ J ]. J Immunother, 2008,31 ( 6 ) : 591 - 598.
  • 2O'Rouke MG, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage Ⅳ melanoma[ J ]. Melanoma Res, 2007,17(5) :316 -322.
  • 3单水阳,吕杰青,何成全,朱林春.绍兴市区1996年~2000年居民恶性肿瘤发病分析[J].中国肿瘤,2003,12(4):214-215. 被引量:32
  • 4Hersey P, Menzies SW, Halliday GM, et al. Phase Ⅰ/Ⅱ study of treatment with dendritic cell vaccines in patients with disseminated melanoma [ J ]. Cancer Immunol Immunother, 2004,53 ( 2 ) : 125 - 134.
  • 5邵纯,宋洁,徐志萍.DC疫苗埋藏式多点皮内注射在肿瘤免疫治疗中的应用及临床观察[J].护士进修杂志,2008,23(7):649-650. 被引量:9
  • 6Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells [ J ]. Cancer Immunol Immunother,2001,50( 1 ) :3 - 15.
  • 7Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-base vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters [ J]. Cancer Immunol Immunother,2009,58 ( 1 ) :1 - 14.
  • 8Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics [J]. J Immunother, 2007,30(1 ) :1 - 15.
  • 9Wheeler C J, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients [ J ]. Cancer Res, 2008,68 (14) : 5955 - 5964.
  • 10Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells[J]. Clin Oncol, 2009,27(6) :945 -952.

二级参考文献5

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部